{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 25 of 81', '4. Hypertrophic obstructive cardiomyopathy, acute myocarditis, amyloidosis, cardiac', 'sarcoidosis, or constrictive pericarditis', '5. Primary valvular heart disease requiring surgery or intervention, or within 3 months', 'after valvular surgery or intervention, or active endocarditis', '6. Acute coronary syndrome (unstable angina, NSTEMI or STEMI) or PCI or CABG', 'within 60 days prior to randomization, or indication for PCI or CABG at the time of', 'randomization', '7. Symptomatic carotid stenosis, or TIA or stroke within 60 days prior to', 'randomization', '8. Complex congenital heart disease', '9. Non-cardiac comorbidity (any of the following)', 'eGFR <30 ml/min/1.73 m\u00b2 calculated by MDRD formula', 'Hepatic insufficiency classified as Child-Pugh B or', 'C', 'Morbid obesity with a BMI >45 kg/m\u00b2', 'Malignancy or other non-cardiac condition limiting life expectancy to <1 year,', 'per physician judgment', 'Requires continuous home oxygen for severe pulmonary disease or has', 'interstitial lung disease', 'Patients with allergies, intolerance or hypersensitivity to the investigational', 'drug or any of the excipients', 'Medical, psychiatric, or other condition or history thereof that in the opinion of', 'the investigator would impair the ability to complete the planned study', 'procedures', '10. Concurrent or anticipated use of PDE5 inhibitors', '11. Concurrent or anticipated use of an sGC stimulator', '12. Concurrent or anticipated use of long-acting and short -acting nitrates or NO donors', 'for any route, including isosorbide dinitrate, isosorbide 5-mononitrate,', 'pentaerythritol tetranitrate, nicorandil, NTG and molsidomine', '13. Previous (within 30 days of randomization) or concomitant participation in another', 'clinical study with investigational medicinal product(s)', '14. Close affiliation with the investigational site; e.g., a close relative of the investigator,', 'dependent person (e.g., employee or student of the investigational site)', '15. Previous assignment to treatment during this study to prevent randomizing patients', 'twice', '16. Illiteracy and /or inability to read the questionnaire for any reason, as the primary', 'endpoint is based on data collected from a self-administered patient-reported', 'questionnaire', '17. Patients who are non-ambulatory or in the view of the investigator are not able to', 'perform a 6MWT. For ATS Statement: Guidelines for the 6MWT see Section 16.1).', '18. Pregnancy or lactation', '19. Previous use of vericiguat', \"20. Known current alcohol and/or illicit drug abuse that may interfere with the patient's\", 'safety and / or compliance at the discretion of the investigator']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 26 of 81', '6.3', 'Withdrawal of patients from study', '6.3.1', 'Withdrawal', 'Withdrawal from study', 'Unnecessary withdrawal of patients from the study follow-up should be avoided and all', 'efforts should be taken to motivate patients to adhere to all study procedures and to be', 'followed until the end of the trial.', 'The investigator should explore all possible options to reach a patient who fails to return to a', 'visit or to respond to the site contact attempts. The site must document all attempts to try to', 'contact the patient in the medical records / source documents. In order to avoid loss-to-follow-', 'up, the investigator should ask the patient at the study start for the contact details of a relative', 'or friend who can be contacted in case the patient cannot be reached. Patients should not be', 'withdrawn from follow-up unless the patient explicitly withdraws consent to be contacted. All', 'efforts should therefore be made to discuss solutions with the patient that would enable the', 'patient to continue with follow-up in order to minimize the number of patients who withdraw', 'such consent. The vital status will be collected for all randomized patients who have not', 'specifically withdrawn consent for further study follow-up by any method (telephone call,', 'email etc.), irrespective of completion of study procedures.', 'Withdrawal from study drug treatment', 'Withdrawal from study drug treatment does not represent withdrawal from the study. As', 'certain data on clinical events beyond study treatment discontinuation may be important to the', \"study, they must be collected through the participant's last scheduled follow-up, even if the\", 'participant has discontinued study treatment. Therefore, all participants who discontinue study', 'treatment prior to completion of the protocol-specified treatment period will still continue to', 'participate in the study.', 'Before permanently discontinuing study drug treatment (either initiated by the patient or the', 'investigator) a temporary interruption should be considered. Patients who have temporarily', 'discontinued from study drug treatment should resume in line with the temporary interruption', 'rules as soon as medically justified in the opinion of the investigator (see Section 7.4). In', 'addition, patients should not be discontinued from the study drug or withdrawn from the study', 'solely for reaching a potential cardiovascular event.', 'If permanent discontinuation of study drug treatment becomes necessary due to intolerance', 'even at the lowest dose step or any other reason, this does not mean that the patient has', 'withdrawn from the study follow-up. Participants may be allowed to begin study treatment', \"again if deemed medically appropriate, unless the participant's treatment assignment has been\", 'unblinded by the investigator/delegate and/or non-study treating physician.', 'For participants who are discontinued from study treatment but continue to be monitored in', 'the study, all visits and procedures, as outlined in the schedule of assessments, should be', 'completed. If the patient is unable to attend scheduled study visits, follow-up of clinical', 'events specified as exploratory endpoints may continue by phone, unless the patient explicitly', 'withdraws his/her consent to any type of follow-up.']\n\n###\n\n", "completion": "END"}